Observational Study of Efficacy and Safety of Travogen Cream and Travocort Cream in the Treatment of Mycoses

An assessment of the efficacy and safety of Travogen cream and Travocort cream in the treatment of local skin mycoses

Completed

Looking for future studies?

Key information

Conditions

Skin Mycoses Bacterial Infections and Mycoses Dermatomycoses Infections Mycoses Skin Diseases Skin Diseases, Infectious Skin and Connective Tissue Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

Kashkin Clinical Research Mycological Institute

Saint Petersburg, Russia

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Diagnosis of skin mycosis

Exclusion criteria

Allergies to study medication

Treatment and study plan

Primary outcomes

Efficacy of Travogen / Travocort in the treatment of skin mycoses / Travogen Cream and Travocort Cream will be prescribed by a physician

Time frame: Baseline to end of study

Secondary outcomes

Patient satisfaction

Time frame: Baseline to end of study

Sponsors and collaborators

Lead sponsor

LEO Pharma

Industry

Collaborators

Bayer

Registry information

Official study title

Observational Study of the Efficacy, Safety and Tolerance of Travogen Cream (Isoconazole) and Travocort Cream (Isoconazole, Diflurcortolone) in the Treatment of Patients With Local Skin Mycosis of Various Etiology and Localization

Important dates

Study start: 2008
Primary completion: 2009
Study completion: 2009
First posted: Jul 25, 2008
Registry last updated: Jun 9, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed